- BioCryst Pharmaceuticals (NASDAQ:BCRX) announces that hereditary angioedema (HAE) patients who were randomized to receive 150 mg of oral, once-daily Orladeyo (berotralstat) at the start of the APeX-2 trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline.
- Median attack rates also decreased from 2.7 attacks/month to 0.0 attacks/month in 16 of 17 months through the same period.
- In addition, on-demand medication use was reduced in HAE patients treated with Orladeyo.
- Orladeyo was generally well-tolerated with fewer drug-related adverse events reported in part 3 (weeks 49-96) as compared to part 1 (weeks 0-24) and part 2 (weeks 25-48).
- 81% of the patients who entered part 3 completed the trial.
- The data are scheduled to be presented at the EAACI Hybrid Congress 2021.